NASDAQ: ADAG

METiS TechBio Partners with Eli Lilly on AI‑Driven Lipid Nanoparticle Delivery – Up to USD 1.1 Billion in Milestones for Tissue‑Specific LNP Discovery
CompanyDeals

METiS TechBio Partners with Eli Lilly on AI‑Driven Lipid Nanoparticle Delivery – Up to USD 1.1 Billion in Milestones for Tissue‑Specific LNP Discovery

METiS TechBio (HKG: 7666), an innovative AI drug delivery company, announced a strategic collaboration with Eli Lilly and Company (NYSE: LLY) focused on the research and discovery of novel lipid…

Sanofi Breaks Ground on Next‑Generation Insulin Manufacturing Facility at Frankfurt BioCampus – Full API Production Planned for 2032

Sanofi Breaks Ground on Next‑Generation Insulin Manufacturing Facility at Frankfurt BioCampus – Full API Production Planned for 2032

Hansoh Pharma Strikes Second ADC Licensing Deal with Roche – USD 400 Million Upfront, Over USD 15 Billion in Potential Milestones

Hansoh Pharma Strikes Second ADC Licensing Deal with Roche – USD 400 Million Upfront, Over USD 15 Billion in Potential Milestones

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Adagene's Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo
CompanyDrug

Adagene’s Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo

Adagene Licenses SAFEbody Platform to Third Arc Bio for Masked CD3 T‑Cell Engagers
CompanyDeals

Adagene Licenses SAFEbody Platform to Third Arc Bio for Masked CD3 T‑Cell Engagers

Adagene Expands Exelixis Collaboration to Include Third Target Using SAFEbody Technology
CompanyDeals

Adagene Expands Exelixis Collaboration to Include Third Target Using SAFEbody Technology

Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates
CompanyDeals

Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates

Sanofi Invests $25 Million in China's Adagene to Advance SAFEbody Program
CompanyDeals

Sanofi Invests $25 Million in China’s Adagene to Advance SAFEbody Program

Adagene Starts Phase II Trial of Muzastotug for Colorectal Cancer
CompanyDrug

Adagene Starts Phase II Trial of Muzastotug for Colorectal Cancer

CompanyDrug

Adagene’s ADG126 Shows Promising Results in Phase Ib/II Study for MSS CRC at ESMO 2024

Show More